Search
PRIMA BIOMED LTD (PRR)

PRIMA BIOMED LTD (PRR)

   Print

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Prima BioMed Limited
Stock Code: PRR
Website: www.primabiomed.com.au
GICS Sub-Industry: Biotechnology
Market Cap ($M): 155
Equiv. Shares (M): 1,066

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.145 $ 0.155 $ 0.155 $ 0.135 $ 0.150 12,026,349 $ -0.005  -3.333 %

Company Overview

Business Description:
Prima BioMed Limited (PRR) is a biotechnology company with a focused on technologies in the fields of cancer immunotherapy and immunology. The company's lead product is the CVac ovarian cancer therapy treatment.

Strategy Analysis:
PRR’s strategy is to provide a global therapy treatment vaccine for ovarian cancer sufferers to extend their life expectancy and improve their quality of life. If this plan comes to fruition then the company will generate significant revenues. The company has recently secured A$25.5m in funding for the development and commercialisation of CVac (their ovarian cancer vaccine).

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2011  A -21.1 -3.7 -- 0.0 0.0 0.0 --
2010  A -10.2 -2.1 -- 0.0 0.0 0.0 --
2009  A -2.9 -0.9 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2009 A 2010 F 2011 F 2009 A 2010 F 2011 F 2009 A 2010 F 2011 F
CSL (CSL) $19,341 M 0.0602 0.0718 0.1564 21.7742 20.3160 17.5683 0.0212 0.0226 0.0247
Mesoblast (MSB) $1,895 M -- -- -- -- 512.3077 -- 0.0000 0.0000 0.0000
Phosphagenics (POH) $179 M -- -- -- 134.6154 -- -- 0.0000 0.0000 0.0000
Prima Biomed (PRR) $160 M -- -- -- -- -- -- 0.0000 -- --
Starpharma (SPL) $439 M -- -- -- -- -- -- 0.0000 0.0000 0.0000

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PRR -- -- 2.38 -- 76.3
Market 1.12 11.1 0.96 2.31 2.55
Sector 0.95 22.0 2.13 7.54 10.31

Directors
Name Position Start Date
Ms Lucinda (Lucy) Hughes Turnbull Non-Executive Chairman 06 October 2010
Mr Albert Yue Ling Wong Non-Executive Deputy Chairman 28 April 2010
Mr Richard Hammel Non-Executive Director 24 January 2005

Management
Name Position
Ian Edward Bangs Chief Financial Officer,Joint Company Secretary
Matt Lehman Chief Operating Officer
Phillip Hains Company Secretary

Calendar of Events
Date Event
26 February 2013 Report (Interim)
28 September 2012 Report (Annual)
29 August 2012 Report (Prelim)
Search for Managed Funds, Superannuation Funds and Retirement Funds Find a Managed Fund Reduce your fees and save money on your Managed Funds with our 100% Entry Fee Rebate 100% Entry Fee Rebate

Login
Email
Password
     Log me in automatically in future
Forgotten password? | Secure Login | Terms & Conditions
Free Membership

Membership benefits...

  • 100% entry fee rebates
  • Cash back on your managed fund investments with our innovative TrailCap™ program
  • Independent research on...
    • over 1,000 managed funds
    • over 300 ASX-listed Companies
    • top performing suburbs/postcodes
  • Access to IPOs/floats & other investment offers
  • Superior investment tools...
    • Portfolio manager
    • Watchlists
    • Alerts
  • Regular investment e-newsletter

Advertisement

Portfolio / Watchlist

Start a new portfolio / view your existing portfolio.
Track all your assets and manage your investments easily.
Trade Shares Online from $19.95^

eNewsletter

Keep up to date with new investments and important news - subscribe to our FREE weekly eNewsletters. Sign up now!
Free Guides

The Essential Guide to Investing in Fixed Income

An educational booklet with information on how to earn more than bank interest on the cash in your investment portfolio.

More details...

News

Hindsight is a wonderful thing - and so is the market

Sydney Morning Herald 26/05/2012 | A huge buying opportunity. It has gone up ever since.

Come hither and run barefoot among my stocks of memories

The Age 26/05/2012 | I WAS reading some old Marcus Today newsletters. From 2003. Let me take you back and allow you to exercise the power of hindsight:

Briefs

Sydney Morning Herald 26/05/2012 | CONSTRUCTION

IN BRIEF

The Age 26/05/2012 | IRON ORE

IN BRIEF

The Age 25/05/2012 | RADIO People are six times more likely to go to an advertiser's website if they have heard the ad on radio, according to research by Colmar Brunton, released by Commercial Radio Australia. The research showed that radio advertising has an immediate effect on people's digital activity, with more than three-quarters of those exposed to advertising visiting a website or Facebook page or searching for the brand online within 24 hours. Commercial Radio Australia chief executive Joan Warner said the ...

Find a beta stock in rebound or rue one that got away

Sydney Morning Herald 24/05/2012 | The brutal selloff in shares between May 1 and May 18 has been very instructive for traders.

More...

Sponsored Links

More from our network...


Jobs

Pave the path to power
Looking to make your move up the career ladder?

Video

MIB3
Men In Black 3: miss the first 10 minutes

TheVine

Canne Film Festival 2012
Red Carpet Carnage at Cannes

Managed Funds

InvestSMART Top performing Shares
Today's Hottest Stocks

Relationships

Find dating success on RSVP, Australia's online dating and online chat site.
Meet Someone Special On RSVP